Related Experiment Video
Updated: Apr 12, 2026

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
Published on: December 5, 2017
Evaluation of HER2 Gene Status in Breast Cancer Samples with Indeterminate Fluorescence in Situ Hybridization by
Vladimira Koudelakova1, Jitka Berkovcova1, Radek Trojanec1
1Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University and University Hospital in Olomouc, Olomouc, Czech Republic.
Abstract:
Administration of drugs targeting HER2 (official symbol ERBB2) is an important component of therapy for breast cancer patients with HER2 amplification/overexpression as determined by in situ hybridization (ISH) and immunohistochemistry (IHC). In approximately 5% of breast cancers, ISH assays fail. In these cases, HER2 protein expression is evaluated by IHC alone that may yield false negatives/positives for poor-quality samples. Therefore, we developed a method that was based on quantitative real-time PCR applicable for DNA from formalin-fixed, paraffin-embedded tissue samples. Its limit of detection was determined with breast cancer cell lines and validated with 223 breast cancer patient samples. On the basis of comparisons with fluorescent ISH (FISH) and IHC data, the sensitivity of the new method was 94.2% and 95.1%, its specificity was 100% and 99.1%, and overall concordance between results obtained with the quantitative real-time PCR method and FISH/IHC was 97.6% for both methods. The quantitative real-time PCR method was then used to evaluate the HER2 status of 198 of 3696 breast cancer tissues that yielded indeterminate FISH results. The HER2 copy number was successfully determined in 69.2% of these indeterminate samples. Thus, the DNA-based technique appears to be a specific, sensitive method for determining HER2 copy numbers when the FISH assay fails, which may complement IHC tests.
Insights
A new quantitative real-time PCR method accurately determines HER2 gene amplification in breast cancer. This DNA-based test offers high sensitivity and specificity, especially when FISH assays fail, improving HER2 testing reliability.
Area of Science:
- Oncology
- Molecular Diagnostics
- Biotechnology
Background:
- HER2 (ERBB2) amplification/overexpression is crucial for breast cancer therapy.
- Current diagnostic methods like in situ hybridization (ISH) and immunohistochemistry (IHC) have limitations.
- ISH assays fail in ~5% of breast cancers, leading to potential diagnostic errors with IHC alone.
Purpose of the Study:
- To develop and validate a quantitative real-time PCR (qPCR) method for determining HER2 DNA copy number.
- To assess the performance of the qPCR method using formalin-fixed, paraffin-embedded (FFPE) breast cancer tissues.
- To provide a reliable alternative diagnostic tool when standard HER2 testing methods are inconclusive.
Main Methods:
- Developed a quantitative real-time PCR assay for DNA extracted from FFPE breast cancer samples.
- Determined the limit of detection using breast cancer cell lines.
- Validated the method with 223 patient samples, comparing results against fluorescent ISH (FISH) and IHC data.
Main Results:
- The qPCR method demonstrated high sensitivity (94.2%-95.1%) and specificity (99.1%-100%) compared to FISH/IHC.
- Overall concordance between qPCR and FISH/IHC was high (97.6%).
- Successfully determined HER2 copy number in 69.2% of samples with indeterminate FISH results.
Conclusions:
- The developed DNA-based qPCR method is a specific and sensitive tool for determining HER2 copy number.
- This qPCR assay effectively complements IHC tests and provides reliable results when FISH assays fail.
- The method improves diagnostic accuracy for HER2 status in breast cancer patients, aiding therapeutic decisions.
More Related Videos
10:21Protocol for HER2 FISH Using a Non-cross-linking, Formalin-free Tissue Fixative to Combine Advantages of Cryo-preservation and Formalin Fixation
Published on: December 25, 2017
03:55Author Spotlight: FISH as a Tool for Precise Gene Amplification Assessment in Cancer Specimens
Published on: July 12, 2024
Related Concept Videos
Real Time RT-PCR
The real-time quantification of the number of amplified products is...
In-situ Hybridization
Types of probes and labels
A probe is a complementary strand of DNA or RNA that binds to corresponding nucleotide sequences in a cell. Many...